A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

This study is open to women aged 18 or older who have advanced solid tumours. Specifically, if you have advanced breast cancer (ER+ HER2- type) that has progressed after a previous treatment called a CDK4/6 inhibitor, or if you have advanced high-grade serous ovarian cancer that has progressed after platinum-based chemotherapy, you might be suitable.

To join, your doctor must agree that participating in this study is a good option for your next treatment. You\'ll need to be generally well enough to take part, meaning you can carry out most daily activities without too much difficulty, and have a reasonable life expectancy. Doctors will also need to be able to measure your cancer to see how the treatment is working.

There are certain reasons why you might not be able to join. For example, if you've recently had other cancer treatments, major surgery, or radiotherapy, you might need to wait a bit. Also, if you're taking certain medications that might interfere with AZD8421, or if you have unresolved side effects from previous treatments that are still severe, you might not be eligible.

If you join this study, you will receive AZD8421, either on its own or in combination with other anti-cancer drugs. You will have regular visits to the clinic so the medical team can monitor your health, check for any side effects, and see how you are responding to the treatment. These visits will involve blood tests, physical examinations, and scans to track the cancer. The total duration of your participation will depend on how you respond to the treatment and the phase of the study you are in, but the medical team will explain this in detail. After finishing the study drug, there will be follow-up visits to continue monitoring your health.